parkinson's disease triple agonist glp-1 gip glucagon clinical trial Beyond insulin: The Intriguing role of in The Road towards Triple Agonists:

The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer

Cayman offers these agents for research use only to support research in metabolic diseases like T2D and obesity

But theres a tradeoff

With so many people interested in using GLP-1 agonists off-label to lose a few extra pounds, what does it mean for this class of drugs?

Although evidence from clinical trials has shown GLP-1 RAs to be safe and efficacious in people living with T2DM and renal impairment, their use is uncommon in this patient population